Xenon Reports Q2 2026 Financial Results and Provides Business Update Aug 6, 2026 04:01PM
Xenon Pharmaceuticals closes $747.5 million public offering Mar 12, 2026 04:01PM
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares Mar 12, 2026 04:01PM
Xenon Pharmaceuticals prices $650 million stock offering at $57 per share Mar 10, 2026 10:39PM
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering Mar 10, 2026 10:39PM


Mar 9, 2026 04:01PM Xenon Pharmaceuticals announces $500 million public offering
Mar 9, 2026 04:01PM Xenon Pharmaceuticals Announces Proposed Public Offering
Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
Feb 25, 2025 04:01PM Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Sep 14, 2023 04:01PM Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit